TY - JOUR
T1 - Interleukin-6 polymorphisms and hematologic malignancy
T2 - A re-appraisal of evidence from genetic association studies
AU - Ziakas, Panayiotis D.
AU - Karsaliakos, Petros
AU - Prodromou, Michael L.
AU - Mylonakis, Eleftherios
N1 - Funding Information:
The Brown University Infectious Diseases Program in Outcomes Research is supported through funding from the Warren Alpert School of Brown University, the Department of Medicine and the Division of Infectious Diseases. The authors report no conflicts of interest.
PY - 2013/11
Y1 - 2013/11
N2 - Context: Interleukin-6 (IL-6) is implicated in the pathophysiology of hematologic neoplasia. Objective: To review the role of IL-6 single nucleotide polymorphisms (SNPs) in hematologic neoplasia. Methods: PubMed and EMBASE search of genetic association studies. Effects were summarized using the model-free generalized odds ratio (ORG), and the mode of inheritance was estimated for significant associations. Results: Seventeen articles provided data on 20 distinct SNPs. The IL-6 receptor rs8192284 was associated with an increased risk of hematologic malignancy (combined ORG 1.42, 95%CI 1.03-1.96), including multiple myeloma (ORG 1.39, 95%CI 0.99-1.95). The IL-6 promoter rs1800795 conferred protection against young adult Hodgkin's disease (ORG 0.68, 95%CI 0.48-0.95). Significant single-study effects for four other SNPs-disease associations were estimated. The IL-6 promoter rs1800795 and rs1800797 were not associated with overall susceptibility to non-Hodgkin's lymphomas. Conclusions: There is accumulating evidence that the IL-6 promoter, receptor and signal transducer SNPs can modify disease susceptibility.
AB - Context: Interleukin-6 (IL-6) is implicated in the pathophysiology of hematologic neoplasia. Objective: To review the role of IL-6 single nucleotide polymorphisms (SNPs) in hematologic neoplasia. Methods: PubMed and EMBASE search of genetic association studies. Effects were summarized using the model-free generalized odds ratio (ORG), and the mode of inheritance was estimated for significant associations. Results: Seventeen articles provided data on 20 distinct SNPs. The IL-6 receptor rs8192284 was associated with an increased risk of hematologic malignancy (combined ORG 1.42, 95%CI 1.03-1.96), including multiple myeloma (ORG 1.39, 95%CI 0.99-1.95). The IL-6 promoter rs1800795 conferred protection against young adult Hodgkin's disease (ORG 0.68, 95%CI 0.48-0.95). Significant single-study effects for four other SNPs-disease associations were estimated. The IL-6 promoter rs1800795 and rs1800797 were not associated with overall susceptibility to non-Hodgkin's lymphomas. Conclusions: There is accumulating evidence that the IL-6 promoter, receptor and signal transducer SNPs can modify disease susceptibility.
KW - Genetic risk
KW - Interleukin-6
KW - Lymphoma
KW - Myeloma
KW - SNP
UR - http://www.scopus.com/inward/record.url?scp=84888857340&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84888857340&partnerID=8YFLogxK
U2 - 10.3109/1354750X.2013.840799
DO - 10.3109/1354750X.2013.840799
M3 - Article
C2 - 24059848
AN - SCOPUS:84888857340
SN - 1354-750X
VL - 18
SP - 625
EP - 631
JO - Biomarkers
JF - Biomarkers
IS - 7
ER -